ImmunoGen, Inc. Announces Conference Call To Discuss Its First Quarter Fiscal Year 2013 Financial Results
. (Nasdaq: IMGN), a
biopharmaceutical company that develops anticancer products using its
Targeted Antibody Payload (TAP) technology and antibody expertise, today
announced that the Company will...
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 26, 2012, to discuss ImmunoGen's financial results for the three-month period ended September 30, 2012 – the first quarter of the Company’s 2013 fiscal year. Management also will provide an update on the Company and more information about the economic terms of the trastuzumab emtansine (T-DM1)-related license with Genentech, a member of the Roche Group. To access the live call by phone, dial 913-312-1472. Passcode: 4483380. The call also may be accessed through the Investor Information section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through November 9, 2012. About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-killing agents specifically to tumor cells. There are now ten TAP compounds in clinical development, of which three are wholly owned by the Company. Marketing applications for trastuzumab emtansine (T-DM1), the most advanced compound using ImmunoGen's TAP technology, have been submitted in the US and Europe. Roche is developing this compound globally under an agreement between ImmunoGen and Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.